NIKKEI 225
33,445.90 +670.08 (+2.04%) HANG SENG
16,463.26 +135.40 (+0.83%) CRUDE OIL
69.41 -2.91 (-4.02%) GOLD FUTURES
2,047.60 +11.30 (+0.55%) DOW
36,115.32 -9.24 (-0.03%) Bitcoin GBP
35,072.02 +307.65 (+0.88%)
BEAM Dec 2023 25.000 call
| Previous close | 4.0000 |
| Open | 4.3000 |
| Bid | 3.0000 |
| Ask | 6.2000 |
| Strike | 25.00 |
| Expiry date | 2023-12-15 |
| Day's range | 4.3000 - 4.8400 |
| Contract range | N/A |
| Volume | |
| Open interest | 3.58k |
ZacksWall Street Analysts Believe Beam Therapeutics Inc. (BEAM) Could Rally 81.29%: Here's is How to Trade
The mean of analysts' price targets for Beam Therapeutics Inc. (BEAM) points to an 81.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Insider Monkey14 Best Short-Term Stocks to Invest In
In this article, we will take a look at 14 best short-term stocks to invest in. To skip our analysis of the recent market activity, you can go directly to see the 5 Best Short-Term Stocks to Invest In. Momentum investing is a key strategy used for short term investments, typically grouped in with other […]
Motley FoolIs Beam Therapeutics Stock a Buy Now?
When it comes to gene-editing companies on the cutting edge, Beam Therapeutics (NASDAQ: BEAM) is keen to be one of the leaders. While it's a bit of a laggard in terms of its pipeline's maturity compared to a few of its competitors, few would claim that its technology platform is unimpressive. Like most biotech stocks that haven't yet commercialized any medicines, Beam is living on borrowed time.
